Robert Allen Britton

US Patent:

20060281110, Dec 14, 2006

Filed:

May 15, 2006

Appl. No.:

11/434081

Inventors:

Robert Britton - East Lansing MI, US
William Uicker - Portland OR, US
Laura Schaeffer - East Lansing MI, US

International Classification:

C12Q 1/68
C07H 21/04
C12N 9/22

US Classification:

435006000, 435199000, 536024100

Abstract:

The present invention discloses that essential and highly conserved GTPases (i.e., for example, YlqF, YqeH, YsxC, or YphC proteins) from participate in ribosome biogenesis. Before this invention, the biological function of the GTPase proteins were unknown. These GTPase proteins are disclosed to affect translation and believed to promote ribosome biogenesis. For example, cells depleted of YlqF protein accumulate a precursor of the 50S subunit that migrates at 45S, suggesting a role in assembly of the large ribosomal subunit. Analysis of the protein content of the 45S particle showed that ribosomal protein L16 is missing from the large subunit. Inhibitors of GTPase-ribosomal interactions (i.e., for example, ribosomal protein or ribosomal nucleic acids) comprise a novel class of antimicrobial compounds.

US Patent:

61329541, Oct 17, 2000

Filed:

Aug 20, 1997

Appl. No.:

8/915498

Inventors:

James R. Lupski - Houston TX
Robert A. Britton - Cambridge MA
Donald L. Court - Frederick MD
Bradford S. Powell - Frederick MD

Assignee:

Baylor College of Medicine - Houston TX
The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

C12Q 168
G01N 3353

US Classification:

435 4

Abstract:

The present invention provides for methods of screening for agents which delay the cell cycle and methods of delaying the cell cycle. Analogues of Era having arginine, histidine, or lysine at amino acid codon 17 are embodied by the present invention. Human and other homologs of bacterial Era amino acid and nucleic acid sequences are provided in the present invention. Vectors, host cells, protein preparations, cell cultures, and compositions comprising said analogue are also set forth in the present invention.

US Patent:

52200990, Jun 15, 1993

Filed:

Aug 31, 1988

Appl. No.:

7/238854

Inventors:

James L. Schreiner - Seabrook TX
Robert A. Britton - Spring TX
Charles T. Dickson - Houston TX
Frederick A. Pehler - Humble TX

Assignee:

Exxon Chemical Patents Inc. - Linden NJ

International Classification:

C07C 712
C10G 2500

US Classification:

585820

Abstract:

A process for purifying linear paraffins in which a hydrocarbon stream containing linear paraffins contaminated with aromatics, sulfur-, nitrogen-, and oxygen-containing compounds, and color bodies, but essentially free of olefins, is contacted with a zeolitic solid adsorbent such as a NaX zeolite or zeolite MgY. After adsorption the zeolitic solid adsorbent is desorbed with an alkyl-substituted aromatic desorbent such as toluene.

US Patent:

50646656, Nov 12, 1991

Filed:

Jan 26, 1990

Appl. No.:

7/471038

Inventors:

Terry J. Klopfenstein - Lincoln NE
Lowell D. Satterlee - Lincoln NE
Robert A. Britton - Lincoln NE
Ralph N. Cleale - Levittown PA

Assignee:

The Board of Regents of The University of Nebraska - Lincoln NE

International Classification:

A23K 118

US Classification:

426 2

Abstract:

To increase the efficiency of utilizing protein in feed by ruminants, feed containing a protein and a reducing sugar are mixed in quantities suitable for the Maillard reaction. The mixture is heated at a temperature, pH and time sufficient to cause early Maillard reactions but not advanced Maillard reactions.

US Patent:

20200269230, Aug 27, 2020

Filed:

Oct 26, 2018

Appl. No.:

16/757577

Inventors:

- Houston TX, US
Reid Laurence Wilson - Houston TX, US
Christopher Stewart - Houston TX, US
Joseph Petrosino - Houston TX, US
Robert Allen Britton - Houston TX, US
Jane Grande-Allen - Houston TX, US
Noah F. Shroyer - Houston TX, US
Mary K. Estes - Houston TX, US

International Classification:

B01L 1/02
B01L 3/00
C12Q 1/18
C12Q 1/70
G01N 33/50

Abstract:

An anaerobic chamber system to evaluate human enteric disease is described herein that can be used to test therapeutic components. In specific embodiments, the anaerobic chamber is used to determine the effect of one or more bacterial communities on ex vivo enteroid cultures. In one application, the anaerobic chamber system is used to determine the efficacy of therapeutic components in ameliorating human enteric disease using personalized medicine.

US Patent:

20200054697, Feb 20, 2020

Filed:

Apr 11, 2018

Appl. No.:

16/604013

Inventors:

- Houston TX, US
Stephen C. Pflugfelder - Houston TX, US
Robert Allen Britton - Houston TX, US

International Classification:

A61K 35/747
A61P 27/04
A61P 37/06

Abstract:

Embodiments of the disclosure encompass methods of treating or preventing an autoimmune disease in an individual. In particular cases, methods comprise administering for delivery to an individual a composition of microbiota. In certain cases, the composition comprises a population of one or more microbiota capable of producing one or more short-chain fatty acids.